• Comment: Doesn't appear to meet WP:NACADEMIC. Don't overpopulate the details of the draft. Gives us the key points with a reliable citation. Safari ScribeEdits! Talk! 05:29, 28 September 2024 (UTC)
  • Comment: still a large amount of unsourced content Theroadislong (talk) 19:03, 3 July 2024 (UTC)
  • Comment: While there are many references, some paragraphs and sections have none at all. I have added citation needed tags in a few places where I felt statements needed to be supported by a reference. Mgp28 (talk) 16:45, 30 June 2024 (UTC)
  • Comment: Please don't add external links to the body of the draft, we don't use them. Theroadislong (talk) 16:46, 17 April 2024 (UTC)
  • Comment: Content like " Moreover, he learned at an early age that one must work hard to achieve one’s goals and dreams" is absolutely not appropriate for an encyclopaedia, just the dry neutral facts are all that is required, with no embellishment. Theroadislong (talk) 17:34, 11 April 2024 (UTC)
  • Comment: Linkedin.com and blogs are not considered reliable independent sources and we don't us external links in the body of an article. Theroadislong (talk) 15:31, 10 April 2024 (UTC)
  • Comment: I am sure that he probably is notable but just not on the evidence provided here. The firts two sources are supposed to confirm that he is "Head of Bacterial Vaccines at Johnson & Johnson" which they do not. In the leded it is claimed that "is a developer and serial inventor of bacterial vaccines." but I struggle to find sources here which say that. Clearly a prolific and senior scientist who probably deserves a place here but the claims need to be matched by the sources which need to be much wider than links to papers he has co-written. It would also help enormously if the references were formatted per Wikipedia's referencing conventiosn so that they can be read by a clickable link.  Velella  Velella Talk   16:15, 9 April 2024 (UTC)
  • Comment: ® is not required anywhere. Non neutral tone includes "successful developer" "successfully" "an expert R&D team from scratch and successfully developed" "a prolific inventor" Theroadislong (talk) 17:26, 5 April 2024 (UTC)
  • Comment: What is repeated mentions of "[brontekst bewerken]" about? Theroadislong (talk) 17:21, 5 April 2024 (UTC)
  • Comment: looks like it has been copied and pasted from somewhere? Theroadislong (talk) 20:10, 4 April 2024 (UTC)


Jan T Poolman Ph.D. (1951) is a Dutch microbiologist and bacterial vaccine expert. His life has been dedicated to the discovery and development of bacterial vaccines. He is known for his role in the development of meningococcal, pneumococcal, pertussis, Haemophilus influenzae type b (Hib), E. coli and S. aureus vaccines.[1][2][3]

Education and Research

edit

Poolman earned his master’s degree from the University of Amsterdam (UVA) in 1975, where he studied chemistry and specialized in the field of microbiology.

He started his career as assistant-professor at the University of Amsterdam, Medical Microbiology department (1975-1986) and the Dutch Reference Laboratory for Bacterial Meningitis, including a NIH Fogarty Fellowship in 1982 and a thesis on the meningococcal cell surface structure.[4] Next he became head of Bacterial Vaccine Research & Development (R&D) at the Dutch National Public Health Institute (RIVM, 1986-1996) initiating DTaPIPVHib, meningococcal and pneumococcal vaccine R&D activities, also acting as project leader for the newly created Dutch-Nordic Consortium combining activities from the Dutch and Scandinavian Public Health Institutes with a focus on pneumococcal vaccine R&D.[2][3]

He then moved on to SmithKline Beecham Biologicals (now GSK Vaccines) in Rixensart, Belgium (1997-2011) as head of bacterial vaccine R&D contributing to the licensure of several bacterial vaccines including whole cell and acellular pertussis and Hib combinations, meningococcal and pneumococcal vaccines. From GSK Dr Poolman moved back from Belgium to The Netherlands to join the vaccine endeavor by Johnson & Johnson (2011-2024), creating a Bacterial Vaccine R&D team with projects centered around adult bacterial vaccines aiming to prevent bacteremia and sepsis induced by E. coli and S. aureus. Extraintestinal Pathogenic E. coli ExPEC 9-valent O-polysaccharide conjugate is currently undergoing a phase 3 efficacy study evaluation.[5]

After his retirement in September 2024 from Johnson & Johnson, Dr Poolman now functions as scientific advisor for several companies/organizations.

Selected publications

edit

Group B Meningococcus:

Cartwright, K; Morris, R; Rümke, H; Fox, A; Borrow, R; Begg, N; Richmond, P; Poolman, J (1999) Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine Vol. 17 (20-21) pp 2612-2619. Doi: 10.1016/s0264-410x(99)00044-4

Haemophilus influenzae type b (Hib):

Poolman, J; Kaufhold, A; De Grave, D; Goldblatt, D (2001) Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine Vol. 19 (17-19) pp 2280-2285. Doi: 10.1016/s0264-410x(00)00517-x

Pertussis:

Capiau, C; Poolman, J; Hoet, B; Bogaerts, H; Andre, F (2003) Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: Difficulties encountered and lessons learned. Vaccine Vol. 21 (19-20) pp 2273-2287. Doi: 10.1016/s0264-410x(03)00107-5

Pneumococcus:

Prymula, R; Peeters, P; Chrobok, V; Kriz, P; Novakova, E; Kaliskova, E; Kohl, I; Lommel, P; Poolman, J; Prieels, JP; Schuerman, L (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study. The Lancet Vol. 367 No. 9512 pp 740-748. Doi: 10.1016/S0140-6736(06)68304-9

Meningococcus ACWY:

Knuf, M; Kieninger-Baum, D; Habermehl, P; Muttonen, P;  Maurer, H; Vink, P; Poolman, J; Boutriau, D (2010) A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine Vol. 28 (3) pp 744-53. Doi: 10.1016/j.vaccine.2009.10.064

ExPEC:

Huttner, A; Hatz, C; van den Dobbelsteen, G; Abbanat, D; Hornacek, A; Frölich, R; Dreyer, AM; Martin, P;  Davies, T; Fae, K; van den Nieuwenhof, I; Thoelen, S; de Vallière, S; Kuhn, A; Bernasconi, E; Viereck, V; Kavvadias, T; Kling, K; Ryu, G; Hülder, T; Gröger, S; Scheiner, D; Alaimo, C; Harbarth, S; Poolman, J; Fonck, VG (2017) Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017 May;17(5):528-537. Doi: 10.1016/S1473-3099(17)30108-1

S. aureus:

Fernandez, J; Sanders, H; Henn, J; Wilson, JM; Malone, D; Buoninfante, A; Willms, M; Chan, R; DuMont, AL; McLahan, C; Grubb, K; Romanello, A; van den Dobbelsteen, G; Torres, VJ; Poolman, JT (2022) Vaccination With Detoxified Leukocidin AB Reduces Bacterial Load in a Staphylococcus aureus Minipig Deep Surgical Wound Infection Model. J Infect Dis. Vol. 225 (8) pp 1460-1470. Doi: 10.1093/infdis/jiab219

Personal life

edit

Poolman is born 16 June 1951 in Broek op Waterland, the Netherlands; he is married and jointly with his second wife they have a mixed family with five children and two grandchildren.

References

edit
  1. ^ Poolman, Jan (2018-12-02). "Building teams to create innovative new vaccines". Human Vaccines & Immunotherapeutics. 14 (12): 2808–2810. doi:10.1080/21645515.2018.1530523. ISSN 2164-5515. PMC 6351015. PMID 30346885.
  2. ^ a b Hendriks, Jan; Blume, Stuart (2016-07-07). "Why might regional vaccinology networks fail? The case of the Dutch-Nordic Consortium". Globalization and Health. 12 (1): 38. doi:10.1186/s12992-016-0176-6. ISSN 1744-8603. PMC 4936226. PMID 27388678.
  3. ^ a b Blume, Stuart S.; Baylac-Paouly, Baptiste (2022). Immunization and states: the politics of making vaccines. Abingdon, Oxon New York, NY: Routledge. ISBN 978-0-367-67227-0.
  4. ^ "Album Academicum". albumacademicum.uva.nl. Retrieved 2024-04-22.
  5. ^ Janssen Research & Development, LLC (2024-03-26). "Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years (Report). clinicaltrials.gov.ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-07-03.{{cite web}}: CS1 maint: numeric names: authors list (link)